A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

被引：0
作者：
Spurgeon, Stephen [1 ]
Chen, Andy I.
Okada, Craig [2 ]
Parekh, Samir [3 ]
Leshchenko, Violetta V. [3 ]
Palmbach, Gundula
Ratterree, Bashi
Subbiah, Nan
Capper, Christine [4 ]
Epner, Elliot M. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA
[2] OHSU Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR USA
[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Penn State Hershey Canc Inst, Hershey, PA USA
[5] Penn State Univ, Hershey Canc Ctr, Hershey, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 50 条
  • [41] Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan
    Ogura, Michinori
    Ishizawa, Kenichi
    Maruyama, Dai
    Uike, Naokuni
    Ando, Kiyoshi
    Izutsu, Koji
    Terui, Yasuhito
    Imaizumi, Yoshitaka
    Tsukasaki, Kunihiro
    Suzuki, Kenshi
    Izumi, Tohru
    Usuki, Kensuke
    Kinoshita, Tomohiro
    Taniwaki, Masafumi
    Uoshima, Nobuhiko
    Suzumiya, Junji
    Kurosawa, Mitsutoshi
    Nagai, Hirokazu
    Uchida, Toshiki
    Fukuhara, Noriko
    Choi, Ilseung
    Ohmachi, Ken
    Yamamoto, Go
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (04) : 470 - 477
  • [42] Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
    Chihara, Dai
    Arons, Evgeny
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Wisch, Laura
    Feurtado, Julie
    James-Echenique, Lacey
    Braylan, Raul
    Calvo, Katherine R.
    Maric, Irina
    Dulau, Alina
    Kreitman, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.
    Budde, Lihua E.
    Zhang, Michelle M.
    Shustov, Andrei R.
    Pagel, John M.
    Warr, Thomas A.
    Chen, Tara L.
    Oliveira, George R.
    Gooley, Ted
    Gopal, Ajay K.
    BLOOD, 2009, 114 (22) : 1423 - 1423
  • [44] Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma
    Gaulin, Charles
    Jain, Preetesh
    Nair, Ranjit
    Iyer, Swaminathan P.
    Lee, Hun Ju
    Fayad, Luis
    Feng, Lei
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Oriabure, Onyeka
    Chen, Wendy
    Xu, Guofan
    Deswal, Anita
    Iliescu, Cezar
    Badillo, Maria
    Ky, Michelle
    Avellaneda, Michelle
    Tangc, Guilin
    Medeiros, L. Jeffrey
    Vega, Francisco
    Flowers, Christopher R.
    Wang, Michael L.
    LEUKEMIA & LYMPHOMA, 2025,
  • [45] Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Romaguera, Jorge E.
    Fayad, Luis E.
    McLaughlin, Peter
    Pro, Barbara
    Rodriguez, Alma
    Wang, Michael
    Weaver, Pamela
    Hartig, Kimberly
    Kwak, Larry W.
    Feldman, Tatyana
    Smith, Judy
    Ford, Peggy
    Goldberg, Stuart
    Pecora, Andrew
    Goy, Andre
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (01) : 47 - 53
  • [46] A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    Park, Steven I.
    Richards, Kristy L.
    Asch, Adam S.
    Olajide, Oludamilola
    Deal, Allison M.
    Ivanova, Anastasia
    Wall, James G.
    Sobol, Anna L.
    Foster, Matthew C.
    Muss, Hyman B.
    Shea, Thomas C.
    BLOOD, 2013, 122 (21)
  • [47] PHASE-II TRIAL OF 2-CHLORODEOXYADENOSINE (2-CDA) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL)
    LEE, E
    KUZEL, T
    SAMUELSON, E
    TALLMAN, M
    ROENIGK, H
    ROSEN, S
    BLOOD, 1993, 82 (10) : A142 - A142
  • [48] Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL).
    Ravandi-Kashani, F
    Kantarjian, H
    Verstovsek, S
    Koller, C
    Faderl, S
    Thomas, D
    Jones, D
    Jorgensen, J
    O'Brien, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 590S - 590S
  • [49] PHASE-II TRIAL OF 2-CHLORO-DEOXYADENOSINE (2-CDA) IN PATIENTS WITH UNTREATED LOW-GRADE NON-HODGKINS-LYMPHOMA
    CANFIELD, V
    VOSE, J
    NICHOLS, C
    BLOOD, 1994, 84 (10) : A168 - A168
  • [50] Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
    Rummel, MJ
    Chow, KU
    Karakas, T
    Jäager, E
    Mezger, J
    von Grünhagen, U
    Schalk, KP
    Burkhard, O
    Hansmann, ML
    Ritzel, H
    Bergmann, L
    Hoelzer, D
    Mitrou, PSS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) : 1739 - 1746
12345